Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
CEO of Foundry
Founder, Gilt Groupe
Founder and Managing Director of DEV
Malaria endangers the health of up to 40 percent of the world’s population and kills up to a million children each year. Elizabeth A. Winzeler, a longtime malaria research scientist now in the Department of Pediatrics at U.C. San Diego School of Medicine, will provide an overview concerning several new chemotypes for the treatment of malaria. Some of these compounds are now in clinical trials, as well as a handful of new chemically-validated anti-malarial drug targets. More information and online registration is here.